CARDINAL HEALTH INC (CAH): 10-K filed August 14, 2024

AI analysis of the 10-K that CARDINAL HEALTH INC filed with the U.S. SEC on August 14, 2024, grounded in the primary-source EDGAR filing.

• Critical Customer Concentration: Heavy revenue dependency on CVS Health and OptumRx in Pharmaceutical segment creates material vulnerability to contract renegotiations or terminations with these two major customers.

• GPO Pricing Pressure: Separate disclosure of Group Purchasing Organization concentration risk signals constrained pricing power and limited negotiating leverage with consolidated customer base.

• Unresolved Opioid Liabilities: Contingent liabilities from ongoing opioid litigation remain uncertain, reflecting industry-wide legal exposure with unpredictable settlement costs that could materially impact financial results.

• Cautious Management Posture: Neutral-to-cautious tone (sentiment 0.15) suggests management acknowledges headwinds without confidence in near-term improvement, indicating conservative outlook on operational environment.

Filing analysis — key questions

Answers are generated from this SEC filing and StockHuntr's analysis. Not investment advice.

What does CARDINAL HEALTH INC (CAH)'s 10-K filed August 14, 2024 say?

Company Overview: Cardinal Health Inc. is a wholesale drug distributor and pharmaceutical services company incorporated in Ohio, with fiscal year ending June 30, 2024, headquartered in Dublin, Ohio. Business Segments: The company operates through pharmaceutical and specialty solutions distribution, with major customers including CVS Health Corporation and OptimumRx, along with Group Purchasing…

Is CAH's 10-K bullish or bearish?

Our analysis rates this filing CAUTIOUS. Cardinal Health faces an ELEVATED concern profile driven by three material structural risks: acute customer concentration (two customers representing substantial PSS revenue), industry-wide opioid litigation exposure with uncertain liability, and channel…

How concerning is CAH's latest 10-K?

Concern level: HIGH (6.2/10). Key factors: Two high-severity customer concentration risks (severity 7/10 each): Material revenue dependency on CVS Health and OptumRx in Pharmaceutical and Specialty Solutions segment creates significant earnings volatility risk if either relationship is lost or materially altered; Opioid litigation exposure (severity 7/10): Ongoing legal proceedings with…

What are the main risks flagged in CAH's 10-K?

Notable risk changes: Explicit disclosure of customer concentration risk with CVS Health and OptumRx identified as major customers in Pharmaceutical and Specialty Solutions segment - material revenue dependency on two customers; GPO (Group Purchasing Organization) concentration risk disclosed as separate material factor affecting pricing power and customer relationships; Ongoing opioid litigation exposure with…

About this analysis

Primary source:
View this 10-K on SEC EDGAR
Additional data:
Yahoo Finance (market data)
Method:
StockHuntr analyzes filings with AI — see our methodology.
Analysis as of:
August 14, 2024
Published by:
StockHuntr

For research and education only. Nothing here is investment advice.

📄

Fetching Filing from SEC

Downloading filing HTML from SEC.gov...

15% Complete
1
Fetch filing from SEC
2
Parse document sections
3
Fetch prior filing
4
Analyze risk factors
5
Analyze management sentiment
6
Extract financial metrics
7
Compare to analyst consensus
8
Run ML prediction model
9
Finalize analysis

Note: Analysis typically takes 30-60 seconds. We're fetching real SEC filing data and running AI analysis on the actual content.